Business · 17/10/2026
AbbVie Presents Long-Term Data on SKYRIZI and RINVOQ for Inflammatory Bowel Disease at UEGW 2026
AbbVie showcased extensive long-term clinical and endoscopic results from its IBD research programs, highlighting the company's leadership in the field, with 20 scientific presentations featuring SKYRIZI (risankizumab) and RINVOQ (upadacitinib).